FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079596123> ?p ?o ?g. }

• W2079596123 endingPage "496" @default.
• W2079596123 startingPage "496" @default.
• W2079596123 abstract "Restless legs syndrome (RLS) is a neurological disorder characterized by unpleasant sensations in the legs and a distressing, irresistible urge to move them. We conducted a systematic review to evaluate efficacy, safety, and comparative effectiveness of pharmacologic treatments for primary RLS.We included randomized controlled trials (RCTs), published in English, reporting efficacy outcomes and harms of pharmacologic treatments for primary RLS of at least 4 weeks' duration. MEDLINE and other databases were searched through June 2012. Reviewers extracted outcomes and adverse events and rated the strength of evidence.We identified 29 eligible RCTs. We found high-strength evidence that the proportion of patients who had a clinically important response (International Restless Legs Syndrome [IRLS] responders), defined as a 50% or greater reduction from baseline in mean IRLS symptom scale scores, was greater with dopamine agonist therapy compared with placebo (61% vs 41%) (risk ratio, 1.60 [95% CI, 1.38-1.86]; 7 trials). Dopamine agonists also improved patient-reported sleep scale scores and quality-of-life measures. High-strength evidence demonstrated that calcium channel alpha-2-delta ligands increased the proportion of IRLS responders compared with placebo (61% vs 37%) (risk ratio, 1.66 [95% CI, 1.33-2.09]; 3 trials). Adverse events associated with dopamine agonists included nausea, vomiting, and somnolence. Alpha-2-delta ligands adverse events included somnolence and unsteadiness or dizziness.On the basis of short-term RCTs that enrolled highly selected populations with long-term high-moderate to very severe symptoms, dopamine agonists and calcium channel alpha-2-delta ligands reduced RLS symptoms and improved sleep outcomes and disease-specific quality of life. Adverse effects and treatment withdrawals due to adverse effects were common." @default.
• W2079596123 created "2016-06-24" @default.
• W2079596123 creator A5007116853 @default.
• W2079596123 creator A5010559732 @default.
• W2079596123 creator A5014041200 @default.
• W2079596123 creator A5021436188 @default.
• W2079596123 creator A5043350291 @default.
• W2079596123 creator A5087797934 @default.
• W2079596123 creator A5089024981 @default.
• W2079596123 date "2013-04-08" @default.
• W2079596123 modified "2023-09-24" @default.
• W2079596123 title "Pharmacologic Therapy for Primary Restless Legs Syndrome" @default.
• W2079596123 cites W1968185119 @default.
• W2079596123 cites W1973999440 @default.
• W2079596123 cites W1977809194 @default.
• W2079596123 cites W1983796764 @default.
• W2079596123 cites W1991024180 @default.
• W2079596123 cites W1994726491 @default.
• W2079596123 cites W1999146151 @default.
• W2079596123 cites W2004489444 @default.
• W2079596123 cites W2012714739 @default.
• W2079596123 cites W2024779266 @default.
• W2079596123 cites W2034430472 @default.
• W2079596123 cites W2040895462 @default.
• W2079596123 cites W2041988152 @default.
• W2079596123 cites W2043201355 @default.
• W2079596123 cites W2043255329 @default.
• W2079596123 cites W2053297910 @default.
• W2079596123 cites W2065434413 @default.
• W2079596123 cites W2075712240 @default.
• W2079596123 cites W2079882077 @default.
• W2079596123 cites W2081152911 @default.
• W2079596123 cites W2082005417 @default.
• W2079596123 cites W2085156752 @default.
• W2079596123 cites W2091605545 @default.
• W2079596123 cites W2094663096 @default.
• W2079596123 cites W2095333141 @default.
• W2079596123 cites W2095827022 @default.
• W2079596123 cites W2098348551 @default.
• W2079596123 cites W2113429239 @default.
• W2079596123 cites W2116642832 @default.
• W2079596123 cites W2118370648 @default.
• W2079596123 cites W2134709345 @default.
• W2079596123 cites W2139903425 @default.
• W2079596123 cites W2141893227 @default.
• W2079596123 cites W2142232805 @default.
• W2079596123 cites W2142434129 @default.
• W2079596123 cites W2145267485 @default.
• W2079596123 cites W2147073836 @default.
• W2079596123 cites W2156567925 @default.
• W2079596123 cites W2157823046 @default.
• W2079596123 cites W2159355230 @default.
• W2079596123 cites W2162586698 @default.
• W2079596123 cites W2169394971 @default.
• W2079596123 cites W222867287 @default.
• W2079596123 cites W90317597 @default.
• W2079596123 doi "https://doi.org/10.1001/jamainternmed.2013.3733" @default.
• W2079596123 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23460396" @default.
• W2079596123 hasPublicationYear "2013" @default.
• W2079596123 type Work @default.
• W2079596123 sameAs 2079596123 @default.
• W2079596123 citedByCount "58" @default.
• W2079596123 countsByYear W20795961232013 @default.
• W2079596123 countsByYear W20795961232014 @default.
• W2079596123 countsByYear W20795961232015 @default.
• W2079596123 countsByYear W20795961232016 @default.
• W2079596123 countsByYear W20795961232017 @default.
• W2079596123 countsByYear W20795961232018 @default.
• W2079596123 countsByYear W20795961232019 @default.
• W2079596123 countsByYear W20795961232020 @default.
• W2079596123 countsByYear W20795961232021 @default.
• W2079596123 countsByYear W20795961232022 @default.
• W2079596123 countsByYear W20795961232023 @default.
• W2079596123 crossrefType "journal-article" @default.
• W2079596123 hasAuthorship W2079596123A5007116853 @default.
• W2079596123 hasAuthorship W2079596123A5010559732 @default.
• W2079596123 hasAuthorship W2079596123A5014041200 @default.
• W2079596123 hasAuthorship W2079596123A5021436188 @default.
• W2079596123 hasAuthorship W2079596123A5043350291 @default.
• W2079596123 hasAuthorship W2079596123A5087797934 @default.
• W2079596123 hasAuthorship W2079596123A5089024981 @default.
• W2079596123 hasConcept C118552586 @default.
• W2079596123 hasConcept C126322002 @default.
• W2079596123 hasConcept C142724271 @default.
• W2079596123 hasConcept C168563851 @default.
• W2079596123 hasConcept C1862650 @default.
• W2079596123 hasConcept C197934379 @default.
• W2079596123 hasConcept C204787440 @default.
• W2079596123 hasConcept C27081682 @default.
• W2079596123 hasConcept C2776750294 @default.
• W2079596123 hasConcept C2779034229 @default.
• W2079596123 hasConcept C2780580376 @default.
• W2079596123 hasConcept C2781210498 @default.
• W2079596123 hasConcept C71924100 @default.
• W2079596123 hasConceptScore W2079596123C118552586 @default.
• W2079596123 hasConceptScore W2079596123C126322002 @default.
• W2079596123 hasConceptScore W2079596123C142724271 @default.
• W2079596123 hasConceptScore W2079596123C168563851 @default.

• next